Preprint Article Version 1 This version is not peer-reviewed

A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-Like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine

Version 1 : Received: 10 October 2024 / Approved: 11 October 2024 / Online: 11 October 2024 (11:01:34 CEST)

How to cite: Vincent, T. S.; Zhu, M.; Parekh, A.; Patel, U.; Cloney-Clark, S.; Klindworth, A.; Silva, D.; Gorinson, A.; Miranda, K.; Wang, M.; Longacre, Z.; Zhou, B.; Cho, I.; Cai, R.; Kalkeri, R.; Fries, L.; Shinde, V.; Plested, J. S. A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-Like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine. Preprints 2024, 2024100884. https://doi.org/10.20944/preprints202410.0884.v1 Vincent, T. S.; Zhu, M.; Parekh, A.; Patel, U.; Cloney-Clark, S.; Klindworth, A.; Silva, D.; Gorinson, A.; Miranda, K.; Wang, M.; Longacre, Z.; Zhou, B.; Cho, I.; Cai, R.; Kalkeri, R.; Fries, L.; Shinde, V.; Plested, J. S. A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-Like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine. Preprints 2024, 2024100884. https://doi.org/10.20944/preprints202410.0884.v1

Abstract

Currently available seasonal influenza vaccines confer variable protection due to antigenic changes resulting from accumulation of diverse mutations. Analysis of new seasonal influenza vaccines is challenging in part due to limitations of the traditional hemagglutination inhibition (HAI) assay with A/H3N2 strains. An improved and objective novel HAI assay was developed using recombinant virus-like particles (VLPs) and egg-derived virus as agglutinins, oseltamivir treatment of VLPs, human red blood cells, and using an automated image reader-based analysis of hemagglutination. HAI validation was demonstrated using four VLP and egg-derived strains, with 46–56 serum samples tested 12 times in duplicate per strain. The validated HAI assay was precise as indicated by the percent geometric coefficient of variation for intra-, inter-, and total-assay precision, and accurate as evidenced by % bias measurements. The assay exhibited linearity, specificity for homologous type/subtype strains, and sensitivity with a starting dilution of 1:10. Assay robustness and sample stability were demonstrated as a % difference compared to reference condition. Validated HAI results were equivalent for singleton and duplicate sample testing and correlated well with a qualified live wild-type influenza microneutralization assay. These findings demonstrate the suitability of this high-throughput novel modified validated HAI assay, for evaluating vaccine immunogenicity and efficacy.

Keywords

hemagglutination inhibition; immunogenicity; influenza vaccine; influenza virus; singleton; validation; virus-like particles; human red blood cells; egg-derived influenza viruses; CypherOne™ Hemagglutination Analyzer (InDevR)

Subject

Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.